Hepatitis B Patient Outcomes from Peg-IFNα-2b Therapy, 203 Patients

A retrospective study of 203 HBeAg-negative Hepatitis B patients with low baseline HBsAg levels treated with pegylated interferon α-2b. The data includes patient outcomes, biomarker levels, and clinical indicators tracked over a median follow-up of 96 weeks to assess sustained HBsAg clearance. The dataset was authored by Chaojing Wen and last updated on 2026-05-20.

Use Cases

• Predicting HBsAg reversion risk based on end-of-treatment HBsAb levels and consolidation therapy duration.
• Analyzing the correlation between HBsAb levels and sustained viral clearance rates.
• Modeling optimal follow-up timelines for patients undergoing Peg-IFNα-2b therapy.

Strengths

• Includes data from 203 patients, providing a specific cohort size.
• Median follow-up duration of 96 weeks with a defined range (72 to 120 weeks).
• Identifies specific predictive factors with statistical significance (e.g., EOT HBsAb >1000 IU/mL associated with 100% sustained clearance).

Limitations

• Row count and column-level documentation are unknown, which limits suitability assessment.
• Data is contained in a DOCX file, which may require parsing to extract structured data.

Provenance

Source

figshare, authored by Chaojing Wen.

Collection Method

Retrospective study analyzing patient records.

Time Range

Follow-up period median 96 weeks (range 72-120 weeks).

Freshness

Last updated 2026-05-20 10:43:29; freshness should be verified.